US Broker Ratings

Agios Pharmaceuticals, Inc. (AGIO) Investor Outlook: A 36% Upside Potential Amidst Robust Revenue Growth

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) presents an intriguing opportunity within the healthcare sector, particularly in the biotechnology industry, where its innovative approach to cellular metabolism could..

Innoviva, Inc. (INVA) Stock Analysis: Exploring a 66.35% Potential Upside in the Biotech Space

Innoviva, Inc. (NASDAQ: INVA) is an intriguing player in the biotech industry that offers a compelling investment opportunity with a potential upside of 66.35%, according to..

Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: High Potential Upside in the Biotech Sector

For investors seeking an opportunity in the biotechnology space, Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) presents an intriguing prospect. With a market capitalization of $2.13 billion, this..

Pacira BioSciences, Inc. (PCRX) Stock Analysis: Uncovering a 23% Upside Potential in Non-Opioid Pain Management

Pacira BioSciences, Inc. (NASDAQ: PCRX) has positioned itself as a prominent player in the healthcare sector, focusing on non-opioid pain management solutions. With a market capitalization..

GoodRx Holdings, Inc. (GDRX) Stock Analysis: Assessing a Potential 18.90% Upside

GoodRx Holdings, Inc. (NASDAQ: GDRX) stands at the intersection of healthcare and technology, offering a unique value proposition for both consumers and investors. As a player..

Astrana Health Inc. (ASTH) Stock Analysis: A Promising 54% Potential Upside in the Healthcare Sector

Astrana Health Inc. (NASDAQ: ASTH), a key player in the healthcare sector, is catching investor attention with its impressive growth metrics and substantial potential upside. With..

Kymera Therapeutics, Inc. (KYMR) Stock Analysis: Unveiling a 17.82% Potential Upside for Biotech Enthusiasts

Kymera Therapeutics, Inc. (NASDAQ: KYMR) stands at the forefront of the biotechnology sector with its innovative approach to drug development. As a clinical-stage biopharmaceutical company, Kymera..

Ocular Therapeutix, Inc. (OCUL) Stock Analysis: Exploring a 171% Potential Upside in the Biotech Sector

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is drawing significant attention in the biotechnology sector, with its impressive potential upside of 171.18% as per analyst target prices. Specializing..

ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: 417% Upside Potential Amidst Robust Revenue Growth

Investors eyeing the healthcare sector might want to focus on ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company known for its innovative approaches to treating severe..

The Pennant Group, Inc. (PNTG) Stock Analysis: Promising 19.78% Upside Potential in Healthcare Services

The Pennant Group, Inc. (NASDAQ: PNTG) is a notable player in the healthcare sector, dedicated to providing essential medical care facilities across the United States. With..

Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis: Strong Buy Ratings and Impressive Revenue Growth

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) has emerged as a noteworthy player in the healthcare sector, particularly within the specialty and generic drug manufacturing industry. With a..

LifeStance Health Group, Inc. (LFST): Investor Outlook Reveals 12% Potential Upside in the Growing Mental Health Market

LifeStance Health Group, Inc. (NASDAQ: LFST), a prominent player in the healthcare sector, specifically within the medical care facilities industry, has been catching the eye of..

Amphastar Pharmaceuticals, Inc. (AMPH) Stock Analysis: Exploring a 10.3% Return on Equity Amidst a Challenging Market

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH), a prominent player in the healthcare sector specializing in the manufacturing of generic and proprietary injectable, inhalation, and intranasal products, offers..

Certara, Inc. (CERT) Stock Analysis: Navigating Through a Modest Valuation and Growth Landscape

Certara, Inc. (NASDAQ: CERT), a prominent player in the healthcare sector, specializes in providing technology-driven services and software products for biosimulation. This innovative approach is instrumental..

Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis: Exploring a 7.51% Potential Upside for Investors

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a Canadian biotechnology firm, is garnering attention among investors, thanks to its promising position in the healthcare sector. Specializing in therapies..

Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Exploring a 20% Potential Upside with Robust Revenue Growth

Protagonist Therapeutics, Inc. (NASDAQ: PTGX), a prominent player in the biotechnology sector, has captured the attention of investors with its impressive market cap of $9.38 billion..

Wave Life Sciences (WVE) Investor Outlook: Unpacking the 335% Potential Upside

Wave Life Sciences, Inc. (NASDAQ: WVE), a pioneering clinical-stage biotechnology company, is generating substantial buzz in the investment community, thanks to an eye-catching potential upside of..

Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis: Exploring a 44% Upside Potential

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) stands out in the healthcare sector with its robust approach to tackling central nervous system (CNS) disorders. As a U.S.-based biopharmaceutical..

agilon health, inc. (AGL): Investor Outlook Reveals 34% Potential Upside Amidst Mixed Performance Metrics

Agilon Health, Inc. (NYSE: AGL) stands at the intriguing intersection of the healthcare sector and medical care facilities industry, specializing in providing healthcare services for seniors..

Crinetics Pharmaceuticals (CRNX) Stock Analysis: Navigating Growth in Rare Endocrine Diseases

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) is making waves in the biotechnology sector, focusing its efforts on discovering and developing innovative therapeutics for rare endocrine diseases and..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds